| Literature DB >> 29176891 |
Eloiza de Rezende1, Rebeca Kawahara1, Mauricio S Peña1, Giuseppe Palmisano1, Beatriz S Stolf1.
Abstract
BACKGROUND: Leishmaniasis is an antropozoonosis caused by Leishmania parasites that affects around 12 million people in 98 different countries. The disease has different clinical forms, which depend mainly on the parasite genetics and on the immunologic status of the host. The promastigote form of the parasite is transmitted by an infected female phlebotomine sand fly, is internalized by phagocytic cells, mainly macrophages, and converts into amastigotes which replicate inside these cells. Macrophages are important cells of the immune system, capable of efficiently killing intracellular pathogens. However, Leishmania can evade these mechanisms due to expression of virulence factors. Different strains of the same Leishmania species may have different infectivity and metastatic phenotypes in vivo, and we have previously shown that analysis of amastigote proteome can give important information on parasite infectivity. Differential abundance of virulence factors probably accounts for the higher virulence of PH8 strain parasites shown in this work. In order to test this hypothesis, we have quantitatively compared the proteomes of PH8 and LV79 lesion-derived amastigotes using a label-free proteomic approach. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2017 PMID: 29176891 PMCID: PMC5720813 DOI: 10.1371/journal.pntd.0006090
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Lesions in BALB/c and C57BL/6 mice infected with L. (L.) amazonensis promastigotes from LV79 and PH8 strains.
A. Lesion areas of BALB/c and C57BL/6 measured weekly during 12 weeks. T-test between PH8 and LV79 in the same mouse strain, **: p<0.01, ***: p<0.001. B. Area under curve for BALB/c mice infected with LV79 and PH8. C. Area under curve for C57BL/6 mice infected with LV79 and PH8, T-test, **: p<0.01. D. Images of BALB/c lesion 12 weeks p.i. with PH8 (upper) and LV79 (lower) promastigotes. E. Parasite recovery from PH8 and LV79 lesions from three independent infections in BALB/c mice. T-test.
Fig 2Lesions in BALB/c mice infected with L. (L.) amazonensis promastigotes from LV79 and PH8 strains for 12 weeks.
HE staining of BALB/c mice footpads infected with PH8 (A) and LV79 (B) with necrosis area (*). Parasite labeling in PH8 (C) and LV79 (D) lesions by IHQ using anti-Leishmania serum and anti-rabbit HRP antibody. In E, higher magnification of IHQ of PH8 lesion, in F, negative control with secondary antibody but no anti-Leishmania serum. A, B, C, D and F 400X magnification, E with 1000x magnification.
Fig 3Comparison between PH8 and LV79 lesion-derived amastigotes regarding infective characteristics.
A. Estimation of amastigote viability by MTT. Three independent experiments, T test, **:p<0.01. B. Trypsin-like activity of amastigote extracts. One experiment (representative of two) with technical triplicates, T test, ***:p<0.001. C. Density of promastigote cultures, indicating efficiency of conversion of amastigotes to promastigotes after 4 days in culture (one experiment with five technical replicates) T test, ***:p<0.001. D. Lesion development graph and E. the respective area under curve after infection with lesion-derived amastigotes from PH8, LV79 and normalized numbers (using viability percentages) of LV79- named as LV79 normalized. Results from three independent experiments, ANOVA followed by Tukey post test, **:p<0.01, ***:p<0.001 (6 weeks: ** for PH8 x LV79, *** for PH8 x LV79norm, 7 and 8 weeks: *** for PH8 x LV79 and LV79norm). F. Representative image in the last day of infection of BALB/c: I, infected with PH8 amastigotes, II, infected with LV79 amastigotes and III, infected with normalized numbers of LV79 amastigotes.
Fig 4Protein comparison in PH8 and LV79 lesion-derived amastigotes.
A. Venn diagram showing the overlap between all identified proteins in PH8 and LV79. B. Heat map representing log2 fold changes of the quantitative data (green—lowest abundance and red—highest abundance) of the differentially expressed proteins (T test, p <0.05). C. Main component analysis based on all proteins identified in LV79 and/or PH8. D. Heat map representing log2 fold changes of the quantitative data of all proteins identified. The first number (1 or 2) after strain name (1, 2 or 3) indicates infection experiment, the second corresponds to the technical replicate.
Proteins with different abundance between LV79 and PH8.
Protein names and uniport ID, fold change relative to PH8, and strain showing higher abundance (ED = exclusively detected). Proteins with fold changes of 2 or more in LV79/PH8 and in PH8/LV79 are depicted in bold font [39].
| Description | Uniprot ID | Fold change LV79/PH8 | Direction |
|---|---|---|---|
| E9BCF0 | 4,62 | Up LV79 | |
| Q4Q259 | 4,37 | Up LV79 | |
| E9B2V9 | 4,20 | Up LV79 | |
| E9BT02 | 3,73 | Up LV79 | |
| E9B4Q3 | 3,26 | Up LV79 | |
| E9AXG9 | 2,53 | Up LV79 | |
| E9ARK6 | 2,44 | Up LV79 | |
| Q4Q6S8 | 2,36 | Up LV79 | |
| Q9U8C3 | 2,13 | Up LV79 | |
| E9B1Y8 | 2,10 | Up LV79 | |
| A4H800 | 2,00 | Up LV79 | |
| ATP synthase subunit alpha | Q4QJF1 | 1,99 | Up LV79 |
| Ribulose-phosphate 3-epimerase | E9B3Z3 | 1,95 | Up LV79 |
| Putative thimet oligopeptidase | A4HF12 | 1,88 | Up LV79 |
| Putative RNA helicase | A4HC04 | 1,88 | Up LV79 |
| Putative uncharacterized protein | E9AY45 | 1,87 | Up LV79 |
| Conserved TPR domain protein | E9B146 | 1,72 | Up LV79 |
| Putative lysophospholipase | Q4QAE7 | 1,61 | Up LV79 |
| Elongation factor 2 | E9ASD6 | 1,58 | Up LV79 |
| Proliferating cell nuclear antigen | Q4QF35 | 1,54 | Up LV79 |
| Grp E protein homolog | E9B0J8 | 1,51 | Up LV79 |
| 14-3-3 protein-like protein | E9AT99 | 1,49 | Up LV79 |
| Uncharacterized protein | E9B3H9 | 1,45 | Up LV79 |
| Endoribonuclease L-PSP (Pb5), putative | E9BG42 | 1,42 | Up LV79 |
| Cytosolic tryparedoxin | A8I4U5 | 1,28 | Up LV79 |
| Proteasome subunit beta type | E9B5M9 | 0,73 | Up PH8 |
| Putative proteasome beta 2 subunit | E9ASE9 | 0,70 | Up PH8 |
| Cysteine protease group B (Fragment) | Q9TWP0 | 0,58 | Up PH8 |
| Uncharacterized protein | E9AV52 | 0,57 | Up PH8 |
| 40S ribosomal protein S3a | E9BRS2 | 0,57 | Up PH8 |
| WGS CADB00000000 data, contig 96 | E8NHS3 | 0,55 | Up PH8 |
| Putative small GTP-binding protein Rab1 | E9AYX8 | 0,53 | Up PH8 |
| Q9TWN9 | 0,50 | Up PH8 | |
| E9ANY1 | 0,47 | Up PH8 | |
| E9AN56 | 0,34 | Up PH8 | |
| Q25319 | 0,31 | Up PH8 | |
| E9AS67 | 0,25 | Up PH8 | |
| Putative uncharacterized protein | E9AP69 | ED LV79 | |
| Heat Shock Protein 70 (Fragment) | A0A075FJL9 | ED LV79 | |
| Peptidyl-prolylcis-trans isomerase | A4HLM4 | ED LV79 | |
| 6- phosphogluconolactonase | E9AYQ1 | ED LV79 | |
| Putative peroxisomal enoyl-coa hydratase | Q4QDY4 | ED LV79 | |
| Putative uncharacterized protein | E9B709 | ED LV79 | |
| Putative mitogen-activated protein kinase | Q4QDK6 | ED LV79 | |
| Putative RNA-binding protein | E9AK98 | ED LV79 | |
| ATP synthase, epsilon chain, putative | A0A088RWN4 | ED LV79 | |
| Tryparedoxin | E9ADX4 | ED LV79 | |
| Uncharacterized protein | E9B476 | ED LV79 | |
| Uncharacterized protein | E9BFN7 | ED LV79 | |
| Putative pyruvate dehydrogenase E1 beta subunit | E9AXQ3 | ED LV79 | |
| Putative pyruvate phosphate dikinase | Q4QGX9 | ED LV79 | |
| Putative farnesyl pyrophosphate synthase | E9AVW8 | ED LV79 | |
| Malate dehydrogenase | Q4Q3J5 | ED PH8 | |
| Clathrin heavy chain | Q4Q1R2 | ED PH8 | |
| Na/H antiporter-likeprotein | A4HCV3 | ED PH8 | |
| Putative GTP-binding protein | Q4Q9V1 | ED PH8 | |
| Eukaryotic translation initiation factor 6 | Q4Q1Y7 | ED PH8 | |
| Uncharacterized protein | E9AZ36 | ED PH8 | |
| Peptidyl-prolylcis-transisomerase | E9BT84 | ED PH8 | |
| Uncharacterized protein | E9B1E2 | ED PH8 | |
| Putative tryparedoxin | E9ALV8 | ED PH8 | |
| Eukaryotic translation initiation factor 3 subunit 7-like | A4HIN8 | ED PH8 |
Fig 5Validation of proteome data by Western blot.
Western blot images and corresponding graphs showing expression of A. GP63, B. CPx in three samples of amastigotes of PH8 and LV79 strains. Statistical analysis by T test, **:p<0.01.